Solara Active Pharma Sciences Analysis

dividend

Pros

Cons

• Solara Active Pharma Sciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
• No need to calculate the sustainability of Solara Active Pharma Sciences's dividends as it is not paying a notable one for India.
• Solara Active Pharma Sciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
• Solara Active Pharma Sciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
• Solara Active Pharma Sciences's dividend is below the markets top 25% of dividend payers in India (3.08%).

future

Pros

• Solara Active Pharma Sciences's earnings growth is expected to exceed the low risk savings rate of 7.2%.
• Solara Active Pharma Sciences's earnings are expected to exceed the low risk growth rate next year.
• An improvement in Solara Active Pharma Sciences's performance (ROE) is expected over the next 3 years.
• Solara Active Pharma Sciences's revenue growth is expected to exceed the India market average.

Cons

• Solara Active Pharma Sciences's earnings are expected to grow by 11.3% yearly, however this is not considered high growth (20% yearly).
• Solara Active Pharma Sciences's earnings growth is positive but not above the India market average.
• Solara Active Pharma Sciences's net income is expected to increase but not above the 50% threshold in 2 years time.
• Solara Active Pharma Sciences is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
• Performance (ROE) is not expected to exceed the current IN Pharmaceuticals industry average.
• Solara Active Pharma Sciences's revenue is expected to increase but not above the 50% threshold in 2 years time.
• Solara Active Pharma Sciences's revenue is expected to grow by 9% yearly, however this is not considered high growth (20% yearly).

health

Pros

• Solara Active Pharma Sciences is profitable, therefore cash runway is not a concern.
• Solara Active Pharma Sciences is profitable, therefore cash runway is not a concern.
• Debt is well covered by operating cash flow (41.6%, greater than 20% of total debt).
• Debt is covered by short term assets, assets are 1.1x debt.
• Solara Active Pharma Sciences's cash and other short term assets cover its long term commitments.

Cons

• Solara Active Pharma Sciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
• Interest payments on debt are not well covered by earnings (EBIT is 2.1x annual interest expense, ideally 3x coverage).
• Solara Active Pharma Sciences's level of debt (53.8%) compared to net worth is high (greater than 40%).
• High level of physical assets or inventory.

management

Pros

• More shares have been bought than sold by Solara Active Pharma Sciences individual insiders in the past 3 months.

Cons

• The average tenure for the Solara Active Pharma Sciences board of directors is less than 3 years, this suggests a new board.
• The average tenure for the Solara Active Pharma Sciences management team is less than 2 years, this suggests a new team.

misc

Pros

Cons

• Solara Active Pharma Sciences is covered by less than 3 analysts.
• Solara Active Pharma Sciences has significant price volatility in the past 3 months.

past

Pros

• Solara Active Pharma Sciences used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
• Solara Active Pharma Sciences has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
• Solara Active Pharma Sciences's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (70.1% vs 22.7%).

Cons

• Solara Active Pharma Sciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).

value

Pros

• Solara Active Pharma Sciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
• Solara Active Pharma Sciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
• Solara Active Pharma Sciences is good value based on assets compared to the IN Pharmaceuticals industry average.
• Solara Active Pharma Sciences is good value based on earnings compared to the IN Pharmaceuticals industry average.
• SOLARA outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
• SOLARA outperformed the Market in India which returned -14.5% over the past year.
• NSEI:SOLARA is up 23.3% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
• NSEI:SOLARA is up 23.3% outperforming the market in India which returned 8% over the past month.

Cons

• Solara Active Pharma Sciences is poor value based on expected growth next year.
• Solara Active Pharma Sciences is overvalued based on earnings compared to the India market.